Shilpa Medicare wins India approval for five-day anti-nausea shot
In short
Shilpa Medicare got final approval in India for its extended-release ondansetron injection. The shot is designed to help prevent nausea for up to five days with one dose.
This matters because it could expand the company’s product line and help patients needing chemotherapy support. The report does not say when sales will start or how much revenue it may add.
What the reporting says
Shilpa Medicare received final approval to market its extended-release ondansetron injection in India, according to a publisher summary. The drug is designed to provide anti-nausea protection for up to five days with a single dose. The reporting also says the company has been seeing strong growth across key businesses, but it does not give sales figures or launch timing.
Why it matters
Shilpa Medicare received final approval in India for an extended-release ondansetron injection intended to provide anti-nausea protection for up to five days from one dose. The report links the approval to the drugmaker’s broader growth across key businesses, but it does not provide launch details or financial impact. The immediate effect is a regulatory green light that may support the company’s pharmaceutical portfolio.